Heart failure drug delivery tested in healthy volunteers

NCT ID NCT07656454

Recruiting now Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This early-stage study tests a new drug called CDR132L in 32 healthy adults. Researchers want to see how much of the drug gets into the blood when given as a shot under the skin compared to an IV drip. The goal is to find the best way to give this medicine to people with heart failure in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CDR132L
What this could lead to: If successful, this study could help determine the best way to give CDR132L to people with heart failure, potentially improving treatment convenience and effectiveness.
What could go wrong: This is a very early Phase 1 study in only 32 healthy people, so results may not predict how the drug works in heart failure patients. The drug may also have unknown side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS HEART FAILURE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Parexel International GmbH
RECRUITING

Berlin, 14050, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.